Quality Improvement Intervention for a Safe Antimicrobial Use Reduction in Critically Ill Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHospital Sirio-Libanes

About this trial

The goal of this clinical trial is to learn if an educational intervention with audit and feedback on physicians and health care professionals who participate in antimicrobial treatment decisions can reduce the use of antimicrobials in adult patients admitted to a sample of Brazilian intensive care units (ICUs). The educational intervention is based on a literature review of current recommendations for a more rational use of antimicrobials and microbiological tests in daily ICU practice.

The main questions it aims to answer are:

* Does the educational intervention reduce the antimicrobial consumption in the intensive care units? * Does this educational intervention aiming to reduce antimicrobial utilization in accordance with the latest guidelines have any safety signals regarding ICU mortality rates or ICU length-of-stay?

Researchers will compare (1) ICUs sequentially randomized to this quality improvement educational intervention aimed at improving antimicrobial utilization to (2) the same ICUs at months where the educational intervention has not been delivered yet.

Each participant ICU will transition to the quality improvement intervention approximately each month, starting at July, 2025. This quality improvement intervention is based on current recommendations for antimicrobial stewardship from regulatory agencies and medical societies, including cognitive aids for physicians to improve decision-making regarding the commencement of antimicrobials, their duration and antimicrobial time-outs. The investigators hypothesize that intensivists (ICU doctors) need to embrace antimicrobial stewardship as a core competence of their daily activities.

Eligibility criteria

Qualifiers

ICU leadership acceptance to participant in the quality improvement intervention;

Hospital infection control leadership acceptance to participant in the quality improvement intervention;

ICU participation in the IMPACTO-MR platform with high quality data;

ICU potential for quality improvement based on a subjective assessment of the ICU and hospital infection leaderships

Disqualifiers

All patients admitted to the intensive care unit

Patients younger than 18 years-old will be excluded from individual-level analysis

Trial design

Treatments tested in this trial

  • Educational Quality Improvement Intervention

Treatment groups

9,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Hospital Sirio-Libanes

Lead sponsor

Hospital do Coracao

Collaborator

Hospital Israelita Albert Einstein

Collaborator

Beneficência Portuguesa de São Paulo

Collaborator